Cumberland Pharmaceuticals Inc. (CPIX)
USD 4.19
(3.2%)
USD 4.19
(3.2%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -6.21 Million USD | -13.61% |
| 2022 | -5.7 Million USD | 25.69% |
| 2021 | -7.67 Million USD | -20.31% |
| 2020 | -6.38 Million USD | 31.29% |
| 2019 | -9.28 Million USD | -25.67% |
| 2018 | -7.39 Million USD | -81.09% |
| 2017 | -4.08 Million USD | -184.79% |
| 2016 | -1.43 Million USD | -28.92% |
| 2015 | -1.11 Million USD | -131.24% |
| 2014 | 3.55 Million USD | 193.62% |
| 2013 | -3.8 Million USD | -143.11% |
| 2012 | 8.81 Million USD | -10.47% |
| 2011 | 9.84 Million USD | 51.49% |
| 2010 | 6.5 Million USD | 12.55% |
| 2009 | 5.77 Million USD | -20.67% |
| 2008 | 7.28 Million USD | 8.28% |
| 2007 | 6.72 Million USD | 202.42% |
| 2006 | 2.22 Million USD | 196.55% |
| 2005 | 749.91 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -2.09 Million USD | -0.55% |
| 2024 Q2 | -1.23 Million USD | 41.01% |
| 2023 Q2 | 22.85 Thousand USD | -93.75% |
| 2023 Q4 | -2.08 Million USD | -11.87% |
| 2023 FY | -6.48 Million USD | -13.61% |
| 2023 Q3 | -1.86 Million USD | -8265.72% |
| 2023 Q1 | 365.57 Thousand USD | 116.05% |
| 2022 Q2 | -1.84 Million USD | -44.72% |
| 2022 Q3 | -266.98 Thousand USD | 85.54% |
| 2022 FY | -5.7 Million USD | 25.69% |
| 2022 Q4 | -2.27 Million USD | -753.15% |
| 2022 Q1 | -1.27 Million USD | 70.69% |
| 2021 Q4 | -4.35 Million USD | -178.5% |
| 2021 Q3 | -1.56 Million USD | -8.89% |
| 2021 Q2 | -1.43 Million USD | -342.72% |
| 2021 Q1 | -324.3 Thousand USD | 81.43% |
| 2021 FY | -7.67 Million USD | -20.31% |
| 2020 Q3 | -1.2 Million USD | 23.55% |
| 2020 FY | -6.38 Million USD | 31.29% |
| 2020 Q1 | -1.84 Million USD | -85.08% |
| 2020 Q2 | -1.58 Million USD | 14.36% |
| 2020 Q4 | -1.74 Million USD | -44.45% |
| 2019 FY | -9.28 Million USD | -25.67% |
| 2019 Q1 | -176.79 Thousand USD | 92.19% |
| 2019 Q4 | -997.4 Thousand USD | 46.0% |
| 2019 Q3 | -1.84 Million USD | -206.97% |
| 2019 Q2 | -601.71 Thousand USD | -240.34% |
| 2018 Q1 | -2.45 Million USD | -171.47% |
| 2018 FY | -7.39 Million USD | -81.09% |
| 2018 Q4 | -2.26 Million USD | -25.23% |
| 2018 Q3 | -1.8 Million USD | -107.93% |
| 2018 Q2 | -868.97 Thousand USD | 64.56% |
| 2017 Q1 | -657.8 Thousand USD | 31.29% |
| 2017 FY | -4.08 Million USD | -184.79% |
| 2017 Q4 | -903.32 Thousand USD | -7.62% |
| 2017 Q3 | -839.34 Thousand USD | 50.06% |
| 2017 Q2 | -1.68 Million USD | -155.53% |
| 2016 Q2 | -105.3 Thousand USD | 78.96% |
| 2016 Q3 | 130.13 Thousand USD | 223.57% |
| 2016 Q4 | -957.37 Thousand USD | -835.69% |
| 2016 FY | -1.43 Million USD | -28.92% |
| 2016 Q1 | -500.58 Thousand USD | -207.71% |
| 2015 Q2 | 673.93 Thousand USD | 16273.45% |
| 2015 FY | -1.11 Million USD | -131.24% |
| 2015 Q1 | 4116.00 USD | -99.56% |
| 2015 Q4 | -162.67 Thousand USD | -160.05% |
| 2015 Q3 | 270.88 Thousand USD | -59.81% |
| 2014 Q4 | 946.13 Thousand USD | -4.34% |
| 2014 FY | 3.55 Million USD | 193.62% |
| 2014 Q2 | 1.21 Million USD | 197.91% |
| 2014 Q1 | 408.05 Thousand USD | 116.51% |
| 2014 Q3 | 989.03 Thousand USD | -18.64% |
| 2013 FY | -3.8 Million USD | -143.11% |
| 2013 Q4 | -2.47 Million USD | -63.2% |
| 2013 Q1 | 1.32 Million USD | -59.24% |
| 2013 Q2 | -1.14 Million USD | -186.01% |
| 2013 Q3 | -1.51 Million USD | -32.81% |
| 2012 Q1 | 646.01 Thousand USD | -62.25% |
| 2012 FY | 8.81 Million USD | -10.47% |
| 2012 Q2 | 1.93 Million USD | 200.29% |
| 2012 Q3 | 2.97 Million USD | 53.57% |
| 2012 Q4 | 3.25 Million USD | 9.19% |
| 2011 Q2 | 3.63 Million USD | 157.94% |
| 2011 Q4 | 1.71 Million USD | -44.77% |
| 2011 FY | 9.84 Million USD | 51.49% |
| 2011 Q3 | 3.09 Million USD | -14.69% |
| 2011 Q1 | 1.4 Million USD | -37.07% |
| 2010 Q3 | 2.44 Million USD | 142.0% |
| 2010 FY | 6.5 Million USD | 12.55% |
| 2010 Q4 | 2.23 Million USD | -8.44% |
| 2010 Q1 | 810.5 Thousand USD | 16.88% |
| 2010 Q2 | 1 Million USD | 24.6% |
| 2009 Q2 | 594.11 Thousand USD | -71.94% |
| 2009 Q1 | 2.11 Million USD | 41.16% |
| 2009 Q3 | 2.37 Million USD | 299.26% |
| 2009 FY | 5.77 Million USD | -20.67% |
| 2009 Q4 | 693.43 Thousand USD | -70.77% |
| 2008 Q2 | 1.83 Million USD | 2.51% |
| 2008 Q1 | 1.79 Million USD | 34.62% |
| 2008 Q4 | 1.49 Million USD | -30.26% |
| 2008 Q3 | 2.15 Million USD | 16.97% |
| 2008 FY | 7.28 Million USD | 8.28% |
| 2007 Q2 | 2.04 Million USD | 63.37% |
| 2007 Q1 | 1.25 Million USD | 31.42% |
| 2007 Q4 | 1.33 Million USD | -36.53% |
| 2007 Q3 | 2.09 Million USD | 2.75% |
| 2007 FY | 6.72 Million USD | 202.42% |
| 2006 FY | 2.22 Million USD | 196.55% |
| 2006 Q1 | -1.2 Million USD | 0.0% |
| 2006 Q4 | 951.58 Thousand USD | -43.85% |
| 2006 Q2 | 780.41 Thousand USD | 164.87% |
| 2006 Q3 | 1.69 Million USD | 117.17% |
| 2005 FY | 749.91 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 166.96 Million USD | 103.72% |
| Embecta Corp. | 221.5 Million USD | 102.804% |
| ANI Pharmaceuticals, Inc. | 46.97 Million USD | 113.223% |
| Dynavax Technologies Corporation | -37.02 Million USD | 83.227% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 96.008% |
| Pacira BioSciences, Inc. | 87.67 Million USD | 107.084% |
| PainReform Ltd. | -9.58 Million USD | 35.196% |
| Aquestive Therapeutics, Inc. | -15.1 Million USD | 58.874% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | -29.79% |
| SCYNEXIS, Inc. | 72.66 Million USD | 108.547% |
| China SXT Pharmaceuticals, Inc. | -2.51 Million USD | -146.93% |
| Cosmos Health Inc. | -21.83 Million USD | 71.551% |
| Journey Medical Corporation | -2.07 Million USD | -199.605% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | -29.79% |
| Safety Shot Inc | -12.18 Million USD | 49.025% |
| Alpha Teknova, Inc. | -35.56 Million USD | 82.536% |
| Intra-Cellular Therapies, Inc. | -159.38 Million USD | 96.103% |
| Bright Green Corporation | -8.89 Million USD | 30.148% |
| Procaps Group, S.A. | 38.97 Million USD | 115.936% |
| Theratechnologies Inc. | -10.62 Million USD | 41.556% |
| Harrow Health, Inc. | 580 Thousand USD | 1170.831% |
| Sonoma Pharmaceuticals, Inc. | -4.7 Million USD | -32.117% |
| Biofrontera Inc. | -22.67 Million USD | 72.612% |
| DURECT Corporation | -36.88 Million USD | 83.161% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -17.875% |
| Cronos Group Inc. | -81.37 Million USD | 92.368% |
| OptiNose, Inc. | -22.74 Million USD | 72.697% |
| Ironwood Pharmaceuticals, Inc. | 209.03 Million USD | 102.971% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | 84.137% |
| RedHill Biopharma Ltd. | 12.63 Million USD | 149.167% |
| Organogenesis Holdings Inc. | 12.52 Million USD | 149.587% |
| Guardion Health Sciences, Inc. | -4.33 Million USD | -43.228% |
| Radius Health, Inc. | -3.92 Million USD | -58.237% |
| Universe Pharmaceuticals INC | -3.52 Million USD | -76.105% |
| ProPhase Labs, Inc. | -21.61 Million USD | 71.264% |
| Phibro Animal Health Corporation | 53.31 Million USD | 111.649% |
| Procaps Group S.A. | 52.32 Million USD | 111.87% |
| Alvotech | -354.86 Million USD | 98.25% |
| TherapeuticsMD, Inc. | -8.52 Million USD | 27.129% |
| Viatris Inc. | 766.2 Million USD | 100.811% |
| Rockwell Medical, Inc. | -6.67 Million USD | 6.884% |
| Aytu BioPharma, Inc. | -5.25 Million USD | -18.211% |
| SIGA Technologies, Inc. | 83.62 Million USD | 107.427% |
| Tilray Brands, Inc. | -174.74 Million USD | 96.446% |
| Lifecore Biomedical, Inc. | 9.33 Million USD | 166.561% |
| Shineco, Inc. | -17.06 Million USD | 63.607% |
| PetIQ, Inc. | 60.01 Million USD | 110.349% |
| Regencell Bioscience Holdings Limited | -4.73 Million USD | -31.121% |
| Incannex Healthcare Limited | -30.04 Million USD | 79.326% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 102.475% |
| Alimera Sciences, Inc. | -1.47 Million USD | -322.217% |
| Silver Spike Investment Corp. | 7.34 Million USD | 184.615% |
| Assertio Holdings, Inc. | -243.53 Million USD | 97.45% |
| Shuttle Pharmaceuticals Holdings, Inc. | -5.89 Million USD | -5.404% |
| Petros Pharmaceuticals, Inc. | -13.61 Million USD | 54.39% |
| Clever Leaves Holdings Inc. | -15.59 Million USD | 60.172% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 69.023% |
| Avadel Pharmaceuticals plc | -137.84 Million USD | 95.494% |
| Hempacco Co., Inc. | -8.81 Million USD | 29.521% |
| Talphera, Inc. | -16.88 Million USD | 63.226% |
| Alvotech | -354.86 Million USD | 98.25% |
| Eagle Pharmaceuticals, Inc. | 53.45 Million USD | 111.619% |
| Lantheus Holdings, Inc. | 364.64 Million USD | 101.703% |
| Currenc Group, Inc. | -6.64 Million USD | 6.545% |
| Kamada Ltd. | 10.06 Million USD | 161.713% |
| Indivior PLC | -4 Million USD | -55.27% |
| Evoke Pharma, Inc. | -7.43 Million USD | 16.419% |
| Flora Growth Corp. | -50.35 Million USD | 87.666% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 69.023% |
| Evolus, Inc. | -49.23 Million USD | 87.385% |
| HUTCHMED (China) Limited | 18.37 Million USD | 133.8% |
| Amphastar Pharmaceuticals, Inc. | 196.98 Million USD | 103.153% |
| Akanda Corp. | -10.05 Million USD | 38.209% |